top of page

Publications

Publications

​​

  1. Avlas S, Kassis H, Itan M, Reichman H, Dolitzky A, Hazut I, Grisaru-Tal S, Gordon Y, Tsarfaty I, Karo-Atar D, Rozenberg P, Bitton A, Munitz A. CD300b regulates intestinal inflammation and promotes repair in colitis. Front Immunol, 2023;14:1050245. doi: 10.3389/fimmu.2023.1050245

  2. Grisaru-Tal S, Munitz A. T cell-eosinophil crosstalk-A new road for effective immune checkpoint blockade in breast cancer. Cancer Cell, 2023;41(1):9-11. doi: 10.1016/j.ccell.2022.11.008.

  3. Dolitzky A, Hazut I, Avlas S, Grisaru-Tal S, Itan M, Zaffran I, Levi-Schaffer F, Gerlic M, Munitz A. Differential regulation of Type 1 and Type 2 mouse eosinophil activation by apoptotic cells. Front Immunol, 2022;13:1041660.doi: 10.3389/fimmu.2022.1041660. 

  4. Rosman Y, Hornik-Lurie T, Meir-Shafrir K, Lachover-Roth I, Cohen-Engler A, Munitz A, Confino-Cohen R.Changes in peripheral blood eosinophils may predict colorectal cancer - A retrospective study. World Allergy Organ J, 2022;15(10):100696. doi: 10.1016/j.waojou.2022.100696.

  5. Bader G, Itan M, Edry-Botzer L, Cohen H, Haskin O, Mozer-Glassberg Y, Harel L, Munitz M*, Marcus Mandelblit N*, Gerlic*. Adaptive immune response to BNT162b2 mRNA vaccine in immunocompromised adolescent patients. Front Immunol, 2023;14:1131965. doi: 10.3389/fimmu.2023.1131965.*-Equal contribution and co-correspondence.

  6. Dolitzky A, Hazut I, Avlas S, Grisaru-Tal S, Itan M, Zaffran I, Levi-Schaffer F, Munitz A. Differential regulation of Type 1 and Type 2 mouse eosinophil activation by apoptotic cells. Front Immunol, 2022; doi: 10.3389/fimmu.2022.1041660

  7. Avlas S, Shani G, Rhone N, Itan M, Dolitzky A, Hazut I, Grisaru-Tal S, Gordon Y, Shoda T, Ballaban A, Ben-Baruch NM, Rochman M, Diesendruck Y, Nahary L, Bitton A, Halpern Z, Benhar I, Varol C, Rothenberg ME, Munitz A. Epithelial cell-expressed type II IL-4 receptor mediates eosinophilic esophagitis. Allergy, 2022 Sep 7. doi: 10.1111/all.15510.

  8. Grisaru-Tal S, Rothenberg ME, Munitz A. Eosinophil-lymphocyte interactions in the tumor microenvironment and following cancer immunotherapy. Nat Immunol. 2022; doi: 10.1038/s41590-022-01291-2.

  9. Dolitzky A, Grisaru-Tal S, Avlas S, Hazut I, Gordon Y, Itan M, Munitz A. Mouse resident  lung eosinophils are dependent on IL-5. Allergy, 2022; doi.org/10.1111/all.15362. PDF

  10. Dolitzky A, Shapira G, Grisaru-Tal S, Hazut I, Avlas S, Gordon Y, Itan M, Shomron N, Munitz A. Transcriptional Profiling of Mouse Eosinophils Identifies Distinct Gene Signatures Following Cellular Activation. Front Immunol, 2021; doi: 10.3389/fimmu.2021.802839. PDF 

  11. Grisaru-Tal S, Dulberg S, Beck L, Zhang C, Itan M, Hediyeh-zadeh S, Caldwell J, Rozenberg P, Dolitzky A, AvlasS, Hazut I, Gordon Y, Shani O, Tsuriel S, Gerlic M, Erez N, Jacquelot N, Belz GT, Rothenberg ME, Davis MJ, Yu H, Geiger T, Madi A, Munitz A. Metastasis-entrained eosinophils enhance lymphocyte-mediated anti-tumor immunity. Cancer Res, 2021; DOI: 10.1158/0008-5472.CAN-21-0839. PDF

  12. Uddin J, Tomar S, Sharma A, Waggoner L, Ganesan V, Marella S,  Yang Y, Noah T, Vanoni S, Patterson A, Zeng C, Foster PS, Newberry R, Bishu S, Kao JY, Rosen MJ, Denson L, King PD, Hoebe K, Divanovic S, Munitz A,Hogan SP.  PIR-B Regulates CD4+ IL17a+ T-Cell Survival and Restricts T-Cell–Dependent Intestinal Inflammatory Responses. Cellular and Molecular Gastroenterology and Hepatology, 2021; https://doi.org/10.1016/j.jcmgh.2021.06.013. PDF

  13. LO Ming, Wolf N; Raulet DH, Akkari L, Pittet MJ, Rodriguez PC, Kaplan RN, Munitz A, Zhang Z, Cheng S, Bhardwaj N. Innate immune cells in the tumor microenvironment. Cancer Cell, 2021: 39;725-729. PDF.

  14. Jacquelot N1, Seillet C, Wang M, Pizzolla A, Liao Y, Hediyeh-Zadeh S, Grisaru-Tal S, Louis C, Huang Q, Schreuder J, Souza-Fonseca-Guimaraes F, de Graaf CA, Thia K, Macdonald S, Camilleri M, Luong K, Zhang S, Chopin M, Molden-Hauer T, Nutt SL, Umansky V, Ciric B, Groom JR, Foster PS, Hansbro PM, McKenzie ANJ, Gray DHD, Behren A, Cebon J, Vivier E, Wicks IP,  Trapani JA, Munitz A, Davis MJ, Shi W, Neeson PJ, Belz GT. PD-1 unleashes ILC2-dependent anti-tumor immunity in melanoma. Nat Immunol; 2021: 22;851–864. PDF

  15. Munitz A*, Yechezkel M, Dickstein Y, Yamin D, Gerlic M*. BNT162b2 Vaccination Effectively Prevents the Rapid Rise of SARS-CoV-2 Variant B.1.1.7 in high risk populations in Israel. Cell Reports Medicine; 2021: In Press. DOI:https://doi.org/10.1016/j.xcrm.2021.100264. 
    ​*-Equal contribution.     PDF 

  16. Munitz A*, Edry-Botzer L, Itan M, Tur-Kaspa R, Dicker D, Marcoviciu D, Goren GM, Mor M, Lev S, Gottesman T, Muhsen K, Cohen D, Stein M, Qimron U, Freund NT, Wine Y, and Gerlic M*. Rapid seroconversion and persistent functional IgG antibodies in severe COVID-19 patients correlates with an IL-12p70 and IL-33 signature. Scientific Reports. 2021. In Press. 11:3461. doi: 10.1038/s41598-021-83019-0 
    *-Equal contribution.     PDF

  17. Grisaru-Tal S, Itan M, Grass GD, Torres-Roca J, Eschrich SA, Gordon Y, Dolitzky A, Hazut I, Avlas S, Jacobsen EA, Ziv-Baran T, Munitz A. Primary tumors from mucosal barrier organs drive unique eosinophil infiltration patterns and clinical associations. Oncoimmunology: DOI. 10.1080/2162402X.2020.1859732. PDF

  18. Lustig Y, Keler S, Kolodny R, Ben-Tal N, Atias-Varon D, Shlush E, Gerlic M, Munitz A, Doolman R, Asraf K, Shlush LI. Potential antigenic cross-reactivity between SARS-CoV-2 and Dengue viruses. Clin Infect Dis. 2020 ciaa1207, https://doi.org/10.1093/cid/ciaa1207. PDF

  19. Bitton A, Avlas S, Reichman H, Itan M, Karo-Atar D, Azouz N, Rozenberg P, Diesendruck Y, Nahary l, Rothenberg ME, Benhar I, Munitz A. A key role for IL-13 signaling via the type 2 IL-4 receptor in experimental atopic dermatitis. Sci Immunol; 2020;5(44). pii: eaaw2938. doi: 10.1126/sciimmunol.aaw2938. PDF

  20. Cohen H, Baram N, Edry-Botzer L, Munitz A, Salomon D, Gerlic M. Vibrio pore-forming leukocidin activates pyroptotic cell death via the NLRP3 inflammasome. Emerg Microbes Infect. 2020;9(1):278-290. doi: 10.1080/22221751.2020.1720526. PDF

  21. Yosef I, Edry-Botzer L, Globus R, Shlomovitz I, Munitz A, Gerlic M, Qimron U. A genetic sytem for biasing the sex ratio in mice. EMBO Rep. 2019;doi: 10.15252/embr.201948269. PDF

  22. Noah TK, Knoop KA, McDonald KG, Gustafsson JK, Waggoner L, Vanoni S, Batie M, Arora K, Naren AP, Wang YH, Lukacs NW, Munitz A, Helmrath MA, Mahe MM, Newberry RD, Hogan SP. IL-13-induced intestinal secretory epithelial cell antigen passages are required for IgE-mediated food-induced anaphylaxis. J Allergy Clin Immunol. 2019;144:1058-1073. PDF

  23. Reichman H, Itan M, Rozenberg P, Yarmolovski T, Brazowski E, Varol C, Gluck N, Shapira S, Arber N, Qimron U, Karo-Atar D, Lee JJ, Munitz A. Activated eosinophils exert distinct anti-tumorigenic activities in colorectal cancer. Cancer Immunol Res. 2019;7:388-400. PDF

  24. Shlomovitz I, Erlich Z, Speir M, Zargarian S, Baram N, Edry-Botzer L, Munitz A, Croker BA, Gerlic M. Necroptosis directly induces the release of full-length biologically active IL-33 in vitro and in an inflammatory disease model. FEBS. 2018; In Press.  PDF

  25. Lee EH, Itan M, Jang J, Gu HJ, Rozenberg P, Mingler MK, Wen T, Yoon J, Park SY, Roh JY, Choi CS, Park WJ, Munitz A, Jung Y. Eosinophils support adipocyte maturation and promote glucose tolerance in obesity. Sci Rep. 2018;8:9894. doi: 10.1038/s41598-018-28371-4.  PDF

  26. Grace JO, Malik M, Reichman H, Munitz A, Barski A, Fulkerson PC. Reuse of public, genome-wide, murine eosinophil expression data for hypotheses development. J Leuk Biol. 2018: 2018: doi: 10.1002/JLB.1MA1117-444R.  PDF

  27. Salamon P, Shefler I, Moshkovits I, Munitz A, Klotzman HK, Mekori Y, Hershko A. IL-33 and IgE stimulate mast cell production of IL-2 and regulatory T cell expansion in allergic dermatitis. Clin Exp Allergy. 2017: 47; 1409-1416.  PDF

  28. Reichman H, Moshkovits I, Itan M, Pasmanik-Chor M, Vogl T, Roth J, Munitz A. Transcriptome profiling of mouse colonic eosinophils reveals a key role for eosinophils in the induction of s100a8 and s100a9 in mucosal healing. Sci Reports. 2017; 7:7117. doi: 10.1038/s41598-017-07738-z.  PDF

  29. Rozenberg P, Reichman H, Zab-Bar I, Itan M, Pasmanik-Chor M, Bouffi C, Qimron U, Bachelet I, Fulkerson PC, Rothenberg ME, Munitz A. CD300f:IL-5 cross-talk inhibits adipose tissue eosinophil homing and subsequent IL-4 production. Sci Reports. 2017; 7:5922. doi: 10.1038/s41598-017-06397-4.  PDF

  30. Amit U, Kain D, Wagner A, Sahu A, Nevo-Caspi Y, Gonen N, Molotski N, Konfino T, Landa N, Naftali-Shani N, Blum G, Merquiol E, Karo-Atar D, Kanfi Y, Paret G, Munitz A, Cohen HY, Ruppin E, Hannenhalli S, Leor J. A New Role for Interleukin-13 Receptor α1 in Myocardial Homeostasis and Heart Failure. J Am Heart Ass. 2017: 6(5). pii: e005108. doi: 10.1161/JAHA.116.005108.  PDF

  31. Goldman SF, Moshkovits I, Filiba A, Tsirulsky Y, Shemesh A, Vronov E, Shagan M, Apte RN, Benharroch D, Karo-Atar D, Dagan R, Munitz A, Mizrachi Nebenzahl Y, Porgador A. Natural killer receptor 1 dampens the development of allergic eosinophilic airway inflammation. PLoS One. 2016:11;e0160779 (doi: 10.1371/journal.pone.0160779).  PDF

  32. Moshkovits I, Reichman H, Karo-Atar D, Rozenberg P, Zigmond E, Ziv-Haberman Y, Ben-Baruch-Morgenstern N, Lampinen M, Carlson M, Itan M, Denson LA, Varol C, Munitz A. A key requirement for CD300f in innate immune responses of eosinophils in colitis. Mucosal Immunol. 2017 Jan;10(1):172-183. doi: 10.1038/mi.2016.37.  PDF

  33. Yosef I, Edgar R, Levy A, Sorek R, Munitz A, Qimron U. Natural selection acts alone to give the appearance of "stress-induced" mutagenesis. Nature Microbiol. 2016:1;6047s. (doi: 10.1038/nmicrobiol.2016.47).  PDF

  34. Ben-Baruch-Morgenstern N, Mingler MK, Stucke EM, Besse JA, Wen T, Reichman H, Munitz A*, Rothenberg ME*. Paired immunoglobulin-like receptor B inhibits IL-13–driven eosinophil accumulation and activation in the esophagus. J Immunol. 2016;197:707-14. (*-Equal contribution).  PDF

  35. Caspi M, Firsow A, Rajkumar R, Skalka N, Moshkovitz I, Munitz A, Pasmanik-Chor M, Greif H, Megido D, Kariv R, Rosenberg DW, Rosin-Arbesfeld R. A flow cytometry-based reporter assay identifies macrolide antibiotics as nonsense mutation read-through agents. J Mol Med. 2015 [Epub ahead of print].  PDF

  36. Knipper JA, Willenborg S, Brinckmann J, Bloch W, Maaß T, Wagener R, Krieg T, Sutherland T, Munitz A, Rothenberg ME, Niehoff A, Richardson R, Hammerschmidt M, Allen JE, Eming SA. Interleukin-4 Receptor α Signaling in Myeloid Cells Controls Collagen Fibril Assembly in Skin Repair. Immunity. 2015;43(4):803-16.  PDF

  37. Moshkovits I, Karo-Atar D, Shik D, Reichman H, Itan M, Ejarque-Ortiz A, Hershko AY, Tian L, Coligan JE, Sayos J, Munitz A. CD300f associates with IL-4 receptor a and is required for IL-4-induced cellular responses. Proc Natnl Acad Science USA; 2015:112;8708-13.  PDF

  38. Karo-Atar D, Bordowitz A, Wand O, Pasmanik-Chor M, Fernandez IE, Itan M, Frenkel R, Herbert DR, Eickelberg O, Munitz A. A protective role for IL-13 receptor a 1 in bleomycin-induced pulmonary fibrosis. Mucosal Immunol: 2016 Jan;9(1):240-53. doi: 10.1038/mi.2015.56.  PDF

  39. Karo-Atar D, Itan M, Pasmanik-Chor M, Munitz A. MicroRNA profiling reveals opposing expression patterns for miR-511 in alternatively and classically activated macrophages. J Asthma. 2014: 18:1-25.  PDF

  40. Shik D, Moshkovits I, Karo-Atar D, Reichman H, Munitz A. IL-33 requires CMRF35-like molecule 1 (CLM-1) expression for induction of myeloid cell activation. Allergy. 2014:69;719-29.  PDF

  41. Ben Baruch-Morgenstern N, Shik D, Moshkovits I, Itan M, Karo-Atar D, Bouffi C, Fulkerson PC, Rashkovan D, Jung S, Rothenberg M, Munitz A.  Paired immunoglobulin-like receptor A is an intrinsic, self-limiting pathway suppressing IL-5-induced eosinophil development. Nat Immunol. 2014:36-44.  PDF

  42. Moshkovits I, Shik D, Itan M, Karo-Atar D, Bernshtein B, Hershko AY, van Lookeren Campagne M, Munitz A. CMRF35-like molecule 1 (CLM-1) regulates eosinophil homeostasis by suppressing cellular chemotaxis. Mucosal Immunol; 2014:7;292-303.  PDF

  43. Karo-Atar D, Moshkovits I, Eickelberg O, Königshoff M, Munitz A. PIR-B regulates pulmonary fibrosis by suppressing profibrogenic properties of alveoalar macrophages. Am J Res Cell Mol Biol. 2013; 48:456-464.  PDF

  44. Semis R, Shai N, Munitz, A, Zaslavsky Z, Polacheck I, Segal E. Pharmacokinetics, tissue distribution and immunomodulatory effect of intralipid formulation of nystatin in mice. J of Antimicrob Chem; 2012;67:1716-21.  PDF

  45. Munitz A, Cole ET, Karo-Atar D, Finkelan FD, Rothenberg ME. Resistin-like molecule alpha regulates IL-13-induced chemokine production but not allergen-induced airway responses. Am J Res Cell Mol Biol; 2012;46:703-13.  PDF

  46. Rothenberg ME, Cole ET, Shik D, Mingler MM, Munitz A. IL-13 receptor 1 differentially regulates aeroallergen induced lung responses. J Immunol; 2011; 187:4873-80.  PDF

  47. Waddell A, Ahrens R, Steinbrecher K, Donovan B, Rothenberg ME, Munitz A, Hogan SP. Colonic eosinophilic inflammation in experimental colitis is mediated by Ly6C(high) CCR2(+) inflammatory monocyte/macrophage-derived CCL11. J Immunol. 2011;186:5993-6003.  PDF

  48. Munitz A, Cole ET, Waddell A, Groschwitz K, Ahrens R, Steinbrecher K, Willson T, Han X, Denson L, Rothenberg ME, Hogan SP. Paired immunoglobulin-like receptor B (PIR-B) negatively regulates macrophage activation in experimental colitis. Gastroenterology. 2010;139:530-41. PDF

  49. Herbert DR, Wang JQ, Hogan SP, Groshwitz K, Khodoun M, Munitz A, Orekov T, Perkins C, Wang Q, Brombacher F, Urban Jr. JF, Rothenberg ME, and Finkelman FD. IL-4 and IL-13 protect against intestinal worms by inducing epithelial cells to secrete RELM-b. J Exp Med. 2009; 206:2947-57.  PDF

  50. Munitz A, Seidu L, Ahrens R, Cole E, Hogan SP, Rothenberg ME. Resistin-like molecule a decreases glucose tolerance during intestinal inflammation. J Immunol. 2009;182:2357-63.  PDF

  51. Lu TX, Munitz A, Rothenberg ME. MicroRNA-21 is up-regulated in allergic airway inflammation and regulates IL-12p35 expression. J Immunol. 2009;182:4994-5002.  PDF

  52. Takeda A, Baffi JZ, Kleinman ME, Cho WG, Nozaki M, Yamada K, Kaneko H, Albuquerque RJ, Dridi S, Saito K, Raisler BJ, Budd SJ, Geisen P, Munitz A, Ambati BK, Green MG, Ishibashi T, Wright JD, Humbles AA, Gerard CJ, Ogura Y, Pan Y, Smith JR, Grisanti S, Hartnett ME, Rothenberg ME, Ambati J. CCR3 is a target for age-related macular degeneration diagnosis and therapy. Nature. 2009;460:225-30.  PDF

  53. Nissim Ben Efraim AH, Munitz A, Sherman Y, Mazer BD, Levi-Schaffer F, Eliashar R. Efficient purification of eosinophils from human tissues: A comparative study. J Immunol Methods. 2009;343:91-6. PDF

  54. Munitz A, Beichler A, Seidu L, Ahrens R, Cole E, Hogan SP, Rothenberg ME. Resistin-like molecule a enhances myeloid cell activation and promotes colitis. J Allergy Clin Immunol. 2008;122:1200-1207.  PDF

  55. Munitz A, McBride ML, Bernstein JB, Rothenberg ME. A dual activation and inhibition role for the paired immunoglobulin-like receptor B (PIR-B) in eosinophils. Blood. 2008;111(12):5694-703.  PDF

  56. Munitz A, Brandt EB, Mingler M, Finkelmen FD, Rothenberg ME. Distinct roles for IL-13 and IL-4 via IL-13 receptor alpha 1 and the type II IL-4 receptor in asthma pathogenesis. Proc Natl Acad Sci U S A. 2008 105:7240-5.  PDF

  57. Ahrens R, Beichler A, Seidu L, Blanchard C, Carey  R, Forbes E, Wilson T,  Cohen E, Ballard E, Munitz A, Lee N, Lee JJ, Rothenberg ME, Denson L, Hogan SP. Macrophage/Intestinal epithelial cell-derived CCL11/eotaxin-1 mediates eosinophil recruitment and function in Pediatric Ulcerative Colitis. J Immunol. 2008;181:7390-9.  PDF

  58. Brandt EB, Munitz A, Orekov T, Mingler MK, McBride M, Finkelman FD, Rothenberg ME. Targeting IL-4/IL-13 signaling to alleviate oral allergen-induced diarrhea. J Allergy Clin Immunol. 2008;122:1200-1207.  PDF

  59. Bachelet I, Munitz A, Berent-Maoz B, Mankuta D, Levi-Schaffer F. Suppression of normal and malignant kit signaling by a bispecific antibody linking kit with CD300a. J Immunol. 2008. 180:6064-9.  PDF

  60. Munitz A, Bachelet I, Finkelman FD, Rothenberg ME, Levi-Schaffer F. CD48 is critically involved in allergic eosinophilic airway inflammation. Am J Respir Crit Care Med. 2007;175:911-8.  PDF

  61. Munitz A, Bachelet I, Moretta A, Moretta L, Levi-Schaffer F. The Inhibitory receptor IRp60 suppresses the effects of eotaxin and IL-5/GM-CSF on human eosinophils. Blood. 2006; 107:1996-2003.  PDF

  62. Munitz A, Bachelet I, Eliashar R, Khodoun M, Finkelman FD, Rothenberg ME, Levi-Schaffer F. CD48 is an allergen and IL-3-induced activation molecule on eosinophils. J Immunol. 2006;177:77-83.  PDF

  63. Bachelet I, Munitz A, Mankuta D, Levi-Schaffer F. Mast cell costimulation by CD226/CD112 (DNAM-1/Nectin-2): a novel interface in the allergic process. J Biol Chem. 2006;281(37):27190-6.  PDF

  64. Munitz A, Bachelet I, Levi-Schaffer F. Reversal of airway inflammation and remodeling in asthma by a bispecific antibody fragment linking CCR3 to CD300a. J Allergy Clin Immunol. 2006;118:1082-9.  PDF

  65. Bachelet I*, Munitz A*, Levi-Schaffer F. Abrogation of allergic reactions by a bispecific antibody fragment linking IgE to CD300a. J Allergy Clin Immunol. 2006;117(6):1314-20.  PDF

  66. Bachelet I*, Munitz A*, Moretta A, Moretta L, Levi-Schaffer F. The Inhibitory receptor IRp60 is expressed and functional on human mast cells. J Immunol. 2005;175:12:7989-95.  PDF

  67. Munitz A, Bachelet I, Fraenkel S, Katz G, Mandelboim O, Simon Hans Uwe, Moretta Lorenzo, Colonna Marco, Levi-Schaffer F. 2B4 (CD244) is expressed and functional on human eosinophils. J Immunol. 2005;174:110-8.  PDF
     

Peer-reviewed reviews

  1. 1.              Munitz A, Jackson DJ. Safety of Eosinophil Depletion. European Respiratory Society Educational Publications. 2021; In Press

  2. 2.              Wechsler ME, Munitz A, Drake MG, Jackson DJ, Wardlaw AJ, Dougan SK, Berdnikovs S, Schleich F, Matucci A, Chanez P, Prazma CM, Howarth P, Weller PF, Merkel PA. Eosinophils in Health and Disease: A State-of-the-Art Review. Mayo Clinic Proceedings, 2021: https://doi.org/10.1016/j.mayocp.2021.04.025. PDF

  3. Grisaru-Tal S, Itan M, Klion AD, Munitz A. A new dawn for eosinophils in the tumor microenvironment. Nat Rev Cancer; 2020. doi: 10.1038/s41568-020-0283-9. PDF

  4. Karo-Atar D, Bitton A, Benhar I, Munitz A. Therapeutic Targeting of the Interleukin-4/Interleukin-13 Signaling Pathway: In Allergy and Beyond. BioDrugs. 2018: doi: 10.1007/s40259-018-0280-7. PDF

  5. Rozenberg P, Reichman H, Moshkovits I, Munitz A. CD300 family receptors regulate eosinophil survival, chemotaxis and effector functions. J Leuk Biol. 2017:doi:10.1002/JLB.2MR1117-433R. PDF

  6. Reichman H, Karo-Atar D, Munitz. A. Emerging roles for eosinophils in the tumor microenvironment. Trends in Cancer. 2016; 2:664-675. DOI: http://dx.doi.org/10.1016/j.trecan.2016.10.002.  PDF

  7. Stein M, Munitz A. Targeting interleukin 5 in asthma and hypereosinophilic syndromes. Recent Pat on Inflamm Allergy Drug Discov. 2010:4;201-9.  PDF

  8. Shik D, Munitz A. Inhibitory receptors in activation and suppression of the immune response”. Clin Exp Allergy. 2010:40; 700-709.  PDF

  9. Munitz A. Inhibitory receptors on myeloid cells: new targets for therapy? Pharmacol Ther. 2010:125; 128-37.  PDF

  10. Munitz A, Levi-Schaffer F. Targeting inhibitory receptors on eosinophils: a direct hit to the Achilles heel. J Allergy Clin Immunol. 2007;119:1382-7.  PDF

  11. Bachelet I, Munitz A, Levi-Schaffer F. Tryptase as an inflammatory marker in allergic disease and asthma. Expert Rev Clin Immunol. 2005:1;63-73.  PDF

  12. Munitz A, Levi-Schaffer F. Eosinophils: ”new” roles for “old” cells. Allergy. 2003;59:268-275.  PDF

Editorials

  1. Munitz A, Hogan SP. Alarming eosinophils to combat cancer. Nat Immunol. 2018; 2019 Mar;20(3):250-252. doi: 10.1038/s41590-019-0318-0.  PDF
     

  2. Karo-Atar D, Munitz A. Is Asthma Paying the Toll? Am J Res Cell Mol Biol. 2018;58:3-4. doi: 10.1165/rcmb.2017-0288ED.  PDF
     

  3. Rosenberg HF, Fryer AD, Munitz A, Bochner BS, Jacoby DB, Levi-Schaffer F, Gleich GJ, Furuta GT, Rothenberg ME, Lacy P, Fulkerson PC, Hogan SP, Ackerman SJ, Foster PS. In Memory and Celebration: Dr. James J. Lee. Clin Exp Allergy. 2017 May 26. doi: 10.1111/cea.1295.  PDF
     

  4. Reichman H, Munitz A. Research Highlight: Harnessing Class II Histone Deacetylases in Macrophages to Combat Breast Cancer. Cell Mol Immunol. 2017:14:575-577. doi: 10.1038/cmi.2017.32.  PDF
     

  5. Munitz A, Karo-Atar D, Foster PS. Asthma Diagnosis: miRNA’s to the rescue. J Allergy Clin Immunol. 2016.  PDF
     

  6. Munitz A, Foster PS. Th9 cells: Above and beyond Th2. J Allergy Clin Immunol. 2012;129:1011-3.  PDF
     

  7. Lacy P, Munitz A. Mutations in CCR3 render it “missing in action”. J Allergy Clin Immunol. 2010: 126:158-9.  PDF
     

Book chapters

  1. Grisaru S, Itan M, Munitz A. Analysis of mouse eosinophil migration and killing of tumor cells. Methods Mol Biol.  2021;2241:89-97. doi: 10.1007/978-1-0716-1095-4_8. PDF

  2. Reichman H. Rozenberg P. Munitz A. “The identification, isolation and analysis of function for mouse eosinophils”. In Current Protocols in Immunology (Wiley, ed. Coligan JE), 2017;119:14.43.1-14.43.22. doi: 10.1002/cpim.35.  PDF

  3. Munitz A. Eosinophil Receptor-Mediated Inhibition. In Eosinophils in health and in disease. (Elsevier, ed. Lee JJ and Rosenberg HF), 2013; pp. 179-188).  PDF

  4. Bachelet I, Munitz A, Levi-Schaffer F. Co-culture of mast cells and fibroblasts: a tool to study their cross-talk, Methods Mol Biol. 2006:315;295-317.
     

Patents

1. Munitz, A., Levi-Schaffer F., Bachelet, I., Moretta, L. and Moretta, A. Bi-specific complexes for targeting cells involved in allergic-type reactions, compositions and uses thereof. International Application No. PCT/IL2005/000358. Filing Date: March 30, 2005.
 

2. Munitz A., Levi-Schaffer F., Rothenberg M.E., Bachelet I. CD48 as a novel target for anti-asthmatic and anti-allergic therapy and as a marker for early prediction of allergy. US Provisional Patent Application No. 60/772,883. Filing Date: February 14, 2006
 

3. Munitz A, Bachelet I, Abu-Horwits A, Ben-Ishay E, Amir Y, Zalevsky Z, Shemer A, Shapiro A. DNA origami acid having uniform activity. US Provisional Patent Application No. 61/813,412. Filing Date: April 18, 2013
 

4. Munitz A, Benhar I, Karo-Atar D, Bitton A. Targeting IL-13 receptor alpha 1 in allergic and fibrotic diseases. US Provisional Patent Application 62/330,276.
 

bottom of page